Forecast

The analysts' average price target is +27,24€ (−1,23%). The median is +27,24€ (−1,23%).

Buy	12
Hold	4
Sell	0

News Go to news feed

Takeover rumors about Catalyst Pharmaceuticals push stock higher

Catalyst Pharmaceuticals' stock rose about 5% on Monday after a report that Angelini Pharma is considering a possible takeover. Angelini is reportedly working with advisers, but talks are still at an early stage. The goal of the Italian family-owned company is to expand its global presence. » More on de.investing.com
Catalyst Pharmaceuticals reaches record high of $26.63

Shares of Catalyst Pharmaceuticals climbed to an all-time high of $26.63, rising 25% over the past six months and delivering a year-to-date return of 12.2%. InvestingPro rates the stock as undervalued (P/E 15.65, PEG 0.52) and highlights stronger liquidity versus debt. For Q4 2025 the company reported EPS of $0.68 (expectation $0.31) and revenue of $152.6 million, driven by Firdapse ($97.6M) and Agamree ($35.3M). Oppenheimer reiterated its "Outperform" rating with a $33.00 price target; Catalyst will also present posters on Duchenne research at the MDA conference. » More on de.investing.com
Catalyst Pharmaceuticals presents forecasts: strong growth for Firdapse and Agamree, Fycompa under generic pressure

At the Barclays conference, Catalyst Pharmaceuticals announced 2026 revenue guidance of $615–645 million, driven by Firdapse ($435–450 million) and Agamree ($140–150 million), while Fycompa is expected to decline to $40–45 million due to generics. The company reported 2025 revenue growth of 20%, available cash of over $700 million, and a $200 million share buyback program. Catalyst plans targeted acquisitions or licensing of drugs for rare diseases with peak sales potential of up to $500 million and emphasizes balancing profitability with investments in growth. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Catalyst Pharma Partners has already paid 0,11€ in dividends. The last payout was in April 2022.

Financials

In the last quarter, Catalyst Pharma Partners had revenue of 129.06m€ and net profit of 55.06m€

(EUR)	Mar 2026	YoY
Revenue	+129.06m	1,27%
Gross profit	+108.17m	5,25%
Net profit	+55.06m	4,99%
EBITDA	+81.28m	8,89%

Fundamentals

Metric	Value
Market capitalization	+3.31b€
Number of shares	122.42m
52-week high/low	+27,94€ - +16,34€
Dividends	No
Beta	0,74
P/E ratio	+17,49
PEG ratio	+2,07
P/B ratio	+3,80
P/S ratio	+6,46

Company profile

Catalyst Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im kommerziellen Stadium, das sich auf die Entwicklung und Vermarktung von Therapien für Menschen mit seltenen, schwächenden, chronischen neuromuskulären und neurologischen Krankheiten in den Vereinigten Staaten konzentriert. Es bietet Firdapse, eine Amifampridinphosphat-Tablette für die Behandlung von Patienten mit Lambert-Eaton-Myasthenie-Syndrom (LEMS), und Ruzurgi für die Behandlung von pädiatrischen LEMS-Patienten an. Das Unternehmen entwickelt auch Firdapse für die Behandlung von MuSK-Antikörper-positiver Myasthenia gravis und spinaler Muskelatrophie Typ 3 sowie zur Behandlung von erblicher Neuropathie mit Neigung zu Drucklähmungen. Es hat Lizenzvereinbarungen mit BioMarin Pharmaceutical Inc. und eine Kooperations- und Lizenzvereinbarung mit Endo Ventures Limited für die Entwicklung und Vermarktung von generischen Sabril-Tabletten. Das Unternehmen war früher unter dem Namen Catalyst Pharmaceutical Partners, Inc. bekannt und änderte im Mai 2015 seinen Namen in Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. wurde im Jahr 2002 gegründet und hat seinen Sitz in Coral Gables, Florida.

Name	Catalyst Pharma Partners
CEO	Richard John Daly
Headquarters	Coral Gables, fl USA
Website	catalystpharma.com
Sector	Health Care
Industry	Biotechnology
IPO	11/08/2006
Employees	182